{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:32:52Z","timestamp":1740720772073,"version":"3.38.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.7759\/cureus.79764","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:22:16Z","timestamp":1740676936000},"source":"Crossref","is-referenced-by-count":0,"title":["Tuberous Sclerosis Due to Deletion of Exons 4\u20138 in TSC2 Gene, Favourably Responding to Phenytoin and Everolimus: A Case Report"],"prefix":"10.7759","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2024.101155","article-title":"Tuberous sclerosis complex: diagnostic features, surveillance, and therapeutic strategies","volume":"51","author":"Arredondo KH","year":"2024","unstructured":"Arredondo KH, J\u00fclich K, Roach ES. Tuberous sclerosis complex: diagnostic features, surveillance, and therapeutic strategies. Semin Pediatr Neurol. 2024, 51:101155. 10.1016\/j.spen.2024.101155","journal-title":"Semin Pediatr Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biom14091190","article-title":"Therapeutic approaches to tuberous sclerosis complex: from available therapies to promising drug targets","volume":"14","author":"Conte E","year":"2024","unstructured":"Conte E, Boccanegra B, Dinoi G, Pusch M, De Luca A, Liantonio A, Imbrici P. Therapeutic approaches to tuberous sclerosis complex: from available therapies to promising drug targets. Biomolecules. 2024, 14:1190. 10.3390\/biom14091190","journal-title":"Biomolecules"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5758\/vsi.240039","article-title":"Management of renal angiomyolipomas in tuberous sclerosis: a case series","volume":"40","author":"Gowda GG","year":"2024","unstructured":"Gowda GG, Tigga MP, Sreenath RH. Management of renal angiomyolipomas in tuberous sclerosis: a case series. Vasc Specialist Int. 2024, 40:40. 10.5758\/vsi.240039","journal-title":"Vasc Specialist Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-212946","article-title":"Rapid resolution of cardiac rhabdomyomas following everolimus therapy","volume":"2015","author":"Choudhry S","year":"2015","unstructured":"Choudhry S, Nguyen HH, Anwar S. Rapid resolution of cardiac rhabdomyomas following everolimus therapy. BMJ Case Rep. 2015, 2015:10.1136\/bcr-2015-212946","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup H","year":"2021","unstructured":"Northrup H, Aronow ME, Bebin EM, et al.. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021, 123:50-66. 10.1016\/j.pediatrneurol.2021.07.011","journal-title":"Pediatr Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148312","article-title":"A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K\/AKT\/mTOR signaling pathway","volume":"909","author":"Fu J","year":"2024","unstructured":"Fu J, Liang P, Zheng Y, Xu C, Xiong F, Yang F. A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K\/AKT\/mTOR signaling pathway. Gene. 2024, 909:148312. 10.1016\/j.gene.2024.148312","journal-title":"Gene"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4238\/2014.March.24.14","article-title":"Mutation screening of TSC1 and TSC2 genes in Chinese Han children with tuberous sclerosis complex","volume":"13","author":"Mi CR","year":"2014","unstructured":"Mi CR, Wang H, Jiang H, Sun RP, Wang GX. Mutation screening of TSC1 and TSC2 genes in Chinese Han children with tuberous sclerosis complex. Genet Mol Res. 2014, 13:2102-106. 10.4238\/2014.March.24.14","journal-title":"Genet Mol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2012.02.002","article-title":"Identification of TSC1 and TSC2 mutations in Korean patients with tuberous sclerosis complex","volume":"46","author":"Jang MA","year":"2012","unstructured":"Jang MA, Hong SB, Lee JH, et al.. Identification of TSC1 and TSC2 mutations in Korean patients with tuberous sclerosis complex. Pediatr Neurol. 2012, 46:222-4. 10.1016\/j.pediatrneurol.2012.02.002","journal-title":"Pediatr Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.156","article-title":"Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients","volume":"19","author":"van den Ouweland AM","year":"2011","unstructured":"van den Ouweland AM, Elfferich P, Zonnenberg BA, et al.. Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients. Eur J Hum Genet. 2011, 19:157-63. 10.1038\/ejhg.2010.156","journal-title":"Eur J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0887-8994(99)00074-0","article-title":"Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy","volume":"21","author":"Lazarowski A","year":"1999","unstructured":"Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol. 1999, 21:731-34. 10.1016\/s0887-8994(99)00074-0","journal-title":"Pediatr Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2013.801300","article-title":"Phenytoin-associated severe hypocalcemia with seizures in a patient with a TSC2-PKD1 contiguous gene syndrome","volume":"35","author":"Nseir G","year":"2013","unstructured":"Nseir G, Golshayan D, Barbey F. Phenytoin-associated severe hypocalcemia with seizures in a patient with a TSC2-PKD1 contiguous gene syndrome. Ren Fail. 2013, 35:866-8. 10.3109\/0886022X.2013.801300","journal-title":"Ren Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater IE","year":"2015","unstructured":"Overwater IE, Bindels-de Heus K, Rietman AB, Ten Hoopen LW, Vergouwe Y, Moll HA, de Wit MC. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia. 2015, 56:1239-45. 10.1111\/epi.13050","journal-title":"Epilepsia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101526","article-title":"Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex","volume":"34","author":"Shoji T","year":"2021","unstructured":"Shoji T, Niida Y, Osawa T, et al.. Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex. Respir Med Case Rep. 2021, 34:101526. 10.1016\/j.rmcr.2021.101526","journal-title":"Respir Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02982-1","article-title":"Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice","volume":"18","author":"Cockerell I","year":"2023","unstructured":"Cockerell I, Christensen J, Hoei-Hansen CE, et al.. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Orphanet J Rare Dis. 2023, 18:377. 10.1186\/s13023-023-02982-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_8","article-title":"Everolimus","author":"Hasskarl J","year":"2018","unstructured":"Hasskarl J. Everolimus. Small Molecules in Oncology: Recent Results in Cancer Research. Springer Cham, 2018. 211:101-23. 10.1007\/978-3-319-91442-8_8"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1077-6","article-title":"Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2\u2009years of age - a multicenter retrospective study","volume":"14","author":"Saffari A","year":"2019","unstructured":"Saffari A, Br\u00f6sse I, Wiemer-Kruel A, et al.. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2\u2009years of age - a multicenter retrospective study. Orphanet J Rare Dis. 2019, 14:96. 10.1186\/s13023-019-1077-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0100","article-title":"Beneficial effects of everolimus on autism and attention-deficit\/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex","volume":"27","author":"Kilincaslan A","year":"2017","unstructured":"Kilincaslan A, Kok BE, Tekturk P, Yalcinkaya C, Ozkara C, Yapici Z. Beneficial effects of everolimus on autism and attention-deficit\/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex. J Child Adolesc Psychopharmacol. 2017, 27:383-88. 10.1089\/cap.2016.0100","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13428","article-title":"Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex","volume":"24","author":"Hatano T","year":"2017","unstructured":"Hatano T, Inaba H, Endo K, Egawa S. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Int J Urol. 2017, 24:780-85. 10.1111\/iju.13428","journal-title":"Int J Urol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:3:2:161","article-title":"Phenytoin poisoning","volume":"3","author":"Craig S","year":"2005","unstructured":"Craig S. Phenytoin poisoning. Neurocrit Care. 2005, 3:161-70. 10.1385\/NCC:3:2:161","journal-title":"Neurocrit Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06157.x","article-title":"Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review","volume":"22","author":"So EL","year":"1981","unstructured":"So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia. 1981, 22:467-73. 10.1111\/j.1528-1157.1981.tb06157.x","journal-title":"Epilepsia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata E","year":"2013","unstructured":"Paplomata E, Zelnak A, O'Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013, 140:453-62. 10.1007\/s10549-013-2630-y","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344397-tuberous-sclerosis-due-to-deletion-of-exons-4-8-in-tsc2-gene-favourably-responding-to-phenytoin-and-everolimus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:22:18Z","timestamp":1740676938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344397-tuberous-sclerosis-due-to-deletion-of-exons-4-8-in-tsc2-gene-favourably-responding-to-phenytoin-and-everolimus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.79764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}